Omeros | OMER - Operating Expenses


Omeros reported $59.16M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Adma Biologics USD 64.2M 12.21M Mar/2026
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
BioMarin Pharmaceutical USD 6.32B 5.69B Jun/2026
Cytokinetics USD 207.8M 7.22M Jun/2026
Gilead Sciences USD 3.95B 19.57B Jun/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Immunic USD 23.33M 2.67M Dec/2025
Insmed USD 526.79M 20.55M Jun/2026
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
MacroGenics USD 42.87M 21.68M Jun/2026
Omeros USD 59.16M 20.13M Jun/2024
Pacira USD 180.54M 7.79M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Rockwell Medical USD 30.41M 1.11M Jun/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
United Therapeutics USD 6.4B 499.2M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026